Expression of somatostatin and dopamine receptors in ACTH-producing tumours

Dedov I.I.; Marova E.I.; Abrosimov A.Iu.; Lapshina A.M.; Grigor'ev A.Iu.; Ablitsov Iu.A.; Kuznetsov N.S.; Goncharov N.P.; Arapova S.D.; Rozhinskaia L.Ia.

doi:https://doi.org/

Dedov I.I.

Endocrinology Research Centre

Marova E.I.

Endocrinology Research Centrer

Abrosimov A.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Lapshina A.M.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Grigor'ev A.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Ablitsov Iu.A.

Natsional'nyĭ mediko-khirurgicheskiĭ tsentr im. N.I. Pirogova, Moskva

Kuznetsov N.S.

Endocrinology Research Centrer

Goncharov N.P.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Arapova S.D.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Rozhinskaia L.Ia.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Expression of somatostatin and dopamine receptors in ACTH-producing tumours

Authors:

Dedov I.I., Marova E.I., Abrosimov A.Iu., Lapshina A.M., Grigor'ev A.Iu., Ablitsov Iu.A., Kuznetsov N.S., Goncharov N.P., Arapova S.D., Rozhinskaia L.Ia.

More about the authors

Journal: Problems of Endocrinology. 2010;56(1): 14‑18

Read: 1608 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Dedov II, Marova EI, Abrosimov AIu, et al. . Expression of somatostatin and dopamine receptors in ACTH-producing tumours. Problems of Endocrinology. 2010;56(1):14‑18. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Abstract:

This study was designed to compare immunoexpression of somatostatin receptors (SR)1-5 and dopamine receptors 2 (DR2) in pituitary and non-pituitary ectopic ACTH-producing tumours. A total of 35 patients were enrolled in the study including 21 with Cushing's disease (CD) and 14 with ACTH-ectopic syndrome (ACTH-ES) associated with carcinoid tumours of lungs (n=11), kidney (n=1), thymus (n=1) and with small-cell lung carcinoma (n=1). All patients with corticotropinomas exhibited expression of SR 1-5 dominated by SR-1 (57%). 81% of these tumours expressed two and more SR subtypes. DR2 expression was documented in 52% of the tumours and co-expression of DR2 with different SR subtypes in 29%. Neoplasms associated with ACTH-ES expressed SR with the predominance of SR-3 (72%). Half of these tumours co-expressed two and more SR subtypes. Expression of DR2 was demonstrated in 50% of the neoplasms associated with ACTH-ES; 38% of them co-expressed SR and DF2.

Keywords:

ACTH-producing tumours

immunoexpression of somatostatin and dopamine receptors

Authors:

Dedov I.I.

Endocrinology Research Centre

Marova E.I.

Endocrinology Research Centrer

Abrosimov A.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Lapshina A.M.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Grigor'ev A.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Ablitsov Iu.A.

Natsional'nyĭ mediko-khirurgicheskiĭ tsentr im. N.I. Pirogova, Moskva

Kuznetsov N.S.

Endocrinology Research Centrer

Goncharov N.P.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Arapova S.D.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Rozhinskaia L.Ia.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Close metadata

References:

Raikhlin N.T., Smirnova E.A., Delektorskaya V.V. Znachenie retseptorov somatostatina i ego analogov v onkologii, obshchei i chastnoi patologii. Mater. II nauch. konf. «Klinicheskaya morfologiya novoobrazovanii endokrinnykh zhelez». M 2007; 143-147.
De Bruin C., Feelders R.A., Lamberts S.W., Hofland L.J. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Rev Endocrinol Metab Dis Open Access 2008;10: 2:91-102. Epub 2008 Jul 19.
Luk'yanchikov V.S. APUD-teoriya v klinicheskom aspekte. Rus med zhurn 2005; 13: 26: 1808-1811.
Marova E.I. Dostizheniya v diagnostike i lechenii bolezni Itsenko-Kushinga. V kn.: Neiroendokrinologiya. Klinicheskie ocherki. Yaroslavl': DIA-press 2005; 132-138.
Gregory A.K., Besser G.M., Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 3: 458-511.
Bochicchio D., Losa M., Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 1995; 80: 11: 3114-3120.
Bychkov M.B., Dgebuadze E.N., Bol'shakova S.A. Melkokletochnyi rak legkogo. Prakt onkol 2005; 6: 4: 213-217.
Wajchenberg B.L., Mendoca B.B., Liberman B. et al. Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 1994; 15: 6: 754-780.
Chrisoulidou A., Pazaitou-Panayiotou K., Georgiou E. et al. Ectopic Cushing's syndrome due to CRH secreting liver metastasis in a patient with medullary thyroid carcinoma. Hormones 2008; 7: 3: 259-262.
Batista D.L., Zhang X., Gejman R. et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006; 91: 11: 4482-4488.
Pivonello R., Ferone D., Lamberts S.W., Colao A. Cabergoline plus lanreotide for ectopic Cushing's syndrome. N Engl J Med 2005; 352: 23: 2457-2458.
Kulaksiz H., Eissele R., Rossler D. et al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumors with subtype specific antibodies. Cut 2002; 50: 1: 52-60.
Pronin V.S., Gitel' E.P., Koloda D.E. Diagnosticheskie vozmozhnosti proby s oktreotidom u bol'nykh s akromegaliei. Mater. nauch. konf. «Baltiiskii forum sovremennoi endokrinologii». St-Peterburg 2008; 97-98.
De Herder W.W., Krenning E.P., Malchoff C.D. et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cishing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 1994; 96: 4: 305-312.
Pivonello R., Ferone D., De Herder W.W. et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004; 89: 5: 2452-2462.
Ray D.W., Littlewood AC., Clark A.J. et al. Human small cell lung cancer cell lines expressing the proopiomelanocortin gene have aberrant glucocorticoid receptor function. J Clin Invest 1994; 93: 4: 1625-1630.
Salgado L.R., Fragoso M.C., Knoepfelmacher M. et al. Ectopic ACTH syndrome: our experience with 25 cases. Eur J Endocrinol 2006; 155: 5: 725-733.
Pivonello R., Ferone D., De Herder W.W. et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 2007; 92: 1: 65-69.
Rocheville M., Lange D.C., Kumar U. et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functiona activity. Science 2000; 288: 5463: 154-157.